Core Insights - Sionna Therapeutics announced positive Phase 1 clinical trial results for SION-719 and SION-451, which are first-in-class NBD1 stabilizers aimed at treating cystic fibrosis (CF) [2][3] - Both compounds were well tolerated in trials, achieving pharmacokinetic targets that suggest potential clinical benefits for CF patients [4][5][6] - The company plans to advance SION-719 to a Phase 2a proof-of-concept trial and SION-451 to a Phase 1 dual combination trial, with both trials expected to start in the second half of 2025 and topline data anticipated in mid-2026 [8][9] Company Development Plans - Sionna plans to initiate a Phase 2a trial for SION-719 as an add-on to standard of care in CF patients, focusing on improving CFTR function and demonstrating its unique mechanism [8] - SION-451 will enter a Phase 1 trial evaluating its combination with other CFTR modulators, aiming to inform future Phase 2b trials [9] Clinical Trial Details - The Phase 1 trials were randomized, double-blind, and placebo-controlled, involving 100 subjects for SION-719 and 110 subjects for SION-451 [4] - No serious adverse events were reported, and most treatment-emergent adverse events were mild to moderate [5] Market Context - The development of NBD1 stabilizers addresses a significant unmet need in CF treatment, as many patients on existing therapies do not achieve normal CFTR function [7] - Sionna's approach aims to restore CFTR function, potentially improving clinical outcomes and quality of life for CF patients [11]

Core Insights - Sionna Therapeutics is focused on developing novel medicines to treat cystic fibrosis (CF) by normalizing the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein [1][3] - The company will present preclinical data on its NBD1 stabilizers, SION-451 and SION-719, in combination with CFTR modulators, galicaftor (SION-2222) and SION-109, at the European Cystic Fibrosis Conference [1][2] Company Overview - Sionna Therapeutics is a clinical-stage biopharmaceutical company aiming to revolutionize CF treatment through innovative medicines that stabilize CFTR's nucleotide-binding domain 1 (NBD1) [3] - The company is developing a pipeline of small molecules targeting the F508del genetic mutation and complementary CFTR modulators to enhance CFTR function [3] Presentation Details - The oral presentation titled "Stabilizers of CFTR NBD1 synergize with galicaftor (SION-2222) or SION-109 to enable full correction of ΔF508-CFTR" will take place on June 6, 2025 [2] - The presentation will be available on Sionna's website under the "Scientific Presentations" section [2]

Core Insights - Sionna Therapeutics has completed Phase 1 dosing for its NBD1 stabilizers SION-719 and SION-451, with topline data expected this quarter [1][6] - The company is financially strong following an upsized IPO, with approximately $354.7 million in cash and cash equivalents, which is projected to fund operations into 2028 [1][9] - Sionna plans to initiate a Phase 2a proof-of-concept trial and at least one dual combination MAD trial in the second half of 2025, with topline data anticipated in mid-2026 [1][6] Pipeline Updates - The Phase 1 trials for SION-719 and SION-451 have been completed, and both compounds have shown to be generally well tolerated [1][6] - Target exposures achieved in the trials suggest potential clinical benefits when combined with Sionna's complementary modulators or as an add-on to current standard of care [6] - The upcoming Phase 2a trial will evaluate an NBD1 stabilizer in combination with the current standard of care in cystic fibrosis patients [6] Business Highlights - Sionna completed an upsized IPO in February 2025, raising approximately $219 million in gross proceeds [4] - The company issued 12,176,467 shares at a public offering price of $18.00 per share, with trading commencing on February 7, 2025 [4] - Research and development expenses for Q1 2025 were $13.7 million, up from $10.2 million in Q1 2024, reflecting increased spending to support the clinical pipeline [7][8] Financial Results - General and administrative expenses for Q1 2025 were $6.0 million, compared to $2.9 million in Q1 2024, primarily due to personnel-related costs [8] - The net loss for Q1 2025 was $16.5 million, an increase from a net loss of $11.8 million in Q1 2024 [8] - As of March 31, 2025, cash, cash equivalents, and marketable securities totaled $354.7 million, including net proceeds from the IPO of $199.6 million [9][17]

Core Viewpoint - Vertex Pharmaceuticals has received an expanded label approval from the European Commission for its cystic fibrosis drug Kaftrio, allowing treatment for all patients aged two years and older with at least one non-class I mutation in the CFTR gene [1][2]. Company Overview - Vertex Pharmaceuticals holds a dominant position in the cystic fibrosis market, being the first company to develop a drug that addresses the underlying cause of the disease [6]. - The company markets multiple cystic fibrosis medications, including Kaftrio (Trikafta in the U.S.), Alyftrek, Symdeko/Symkevi, Orkambi, and Kalydeco [6][3]. Market Impact - The expanded label for Kaftrio will make nearly 4,000 additional cystic fibrosis patients eligible for treatment in the European region [2]. - Vertex's cystic fibrosis sales have shown significant growth, with Kaftrio contributing $10.24 billion in product sales in 2024, reflecting a year-over-year increase of approximately 15% [7]. Future Developments - Vertex is developing an mRNA therapeutic, VX-522, in collaboration with Moderna for approximately 5,000 cystic fibrosis patients who do not produce CFTR protein. The single ascending dose portion of the phase I/II clinical study is complete, with data from the ongoing multiple ascending dose portion expected in the first half of 2025 [8]. Stock Performance - Year to date, Vertex's stock has gained 18%, outperforming the industry, which has seen a 7% decline [4].

Table of Contents As filed with the Securities and Exchange Commission on February 3, 2025. Registration No. 333-284352 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sionna Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 84-2801521 (Primary Standard Industrial Classification Code Number) (I.R.S. Em ...

Table of Contents As filed with the Securities and Exchange Commission on January 17, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sionna Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 84-2801521 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Num ...